MIAMI, FL -- (MARKET WIRE) -- November 21, 2006 -- DOR BioPharma, Inc. (OTCBB: DORB) (“DOR” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted the Company’s New Drug Application (“NDA”) for orBec® (oral beclomethasone dipropionate) for the treatment of gastrointestinal Graft-versus-Host disease (“GI GVHD”). The FDA has granted the orBec® NDA application a standard review designation and established a target action date of July 21, 2007 for completion of review of the NDA in accordance with The Prescription Drug User Fee Act (“PDUFA”). The FDA’s Acceptance of the filing indicates the FDA has determined that the NDA is sufficiently complete to permit a substantive review.
